title: High frequency of parvovirus B19 DNA in bone marrow samples from rheumatic patients.
abstract: BACKGROUND
  Human parvovirus B19 (B19) polymerase chain reaction (PCR) is now a routine analysis and serves as a diagnostic marker as well as a complement or alternative to B19 serology. The clinical significance of a positive B19 DNA finding is however dependent on the type of tissue or body fluid analysed and of the immune status of the patient.
  
  
  OBJECTIVE
  To analyse the clinical significance of B19 DNA positivity in bone marrow samples from rheumatic patients.
  
  
  METHODS
  Parvovirus B19 DNA was analysed in paired bone marrow and serum samples by nested PCR technique. Serum was also analysed for B19-specific IgG and IgM antibodies and the results were compared with clinical and epidemiological data.
  
  
  CONCLUSIONS
  B19 IgG was found in 41 of 50 patients (82%) whereas none was B19 IgM positive. The serologic evaluation showed that none of the patients had acute B19 infection. However, B19 DNA was detected by PCR in 13 of 50 (26%) bone marrow samples from these patients indicating a high frequency of persistent infection compared with previous reports of patient groups and healthy controls. In the study, 22 patients had rheumatoid arthritis (RA) and 7 of these RA patients were B19 DNA positive in bone marrow. Rheumatoid factor was positive in 4 of the 7 B19 DNA positive RA patients as compared with Rheumatoid factor positivity in all of the 15 B19 DNA negative RA patients. Erosive arthritis in X-ray was less common in the B19 DNA positive group than in the B19 DNA negative group. A high frequency of parvovirus B19 DNA was thus detected in bone marrow samples in rheumatic patients. The clinical data does not support a direct association between B19 PCR positivity and rheumatic disease manifestation. Therefore, the clinical significance of B19 DNA positivity in bone marrow samples from rheumatic patients must be interpreted with caution.
authors.affiliation: Clinic of Infectious Diseases, Södra Alvsborg Hospital, S-50182 Borås, Sweden.
authors.forename: Anders
authors.initials: A
authors.lastname: Lundqvist
authors.forename: Adiba
authors.initials: A
authors.lastname: Isa
authors.forename: Thomas
authors.initials: T
authors.lastname: Tolfvenstam
authors.forename: Göran
authors.initials: G
authors.lastname: Kvist
authors.forename: Kristina
authors.initials: K
authors.lastname: Broliden
mesh_terms: D000293:Adolescent; D000328:Adult; D000368:Aged; D000369:Aged, 80 and over; D000914:Antibodies, Viral / Q000097:blood; D001168:Arthritis / Q000821:virology; D001172:Arthritis, Rheumatoid / Q000821:virology; D001853:Bone Marrow / Q000821:virology*; D004279:DNA, Viral / Q000032:analysis* / Q000097:blood; D005260:Female; D006801:Humans; D007074:Immunoglobulin G / Q000097:blood; D007075:Immunoglobulin M / Q000097:blood; D008297:Male; D008875:Middle Aged; D010322:Parvoviridae Infections / Q000453:epidemiology / Q000821:virology*; D016732:Parvovirus B19, Human / Q000235:genetics / Q000302:isolation & purification*; D016133:Polymerase Chain Reaction / Q000379:methods; D012216:Rheumatic Diseases / Q000453:epidemiology / Q000821:virology*; D012217:Rheumatoid Factor / Q000097:blood
chemical_list: D000914:Antibodies, Viral; D004279:DNA, Viral; D007074:Immunoglobulin G; D007075:Immunoglobulin M; D012217:Rheumatoid Factor